Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the...
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma
China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a...
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm...
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market...
CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting...
Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales
China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...
China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs
The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...
OrbusNeich Files for IPO on Hong Kong Stock Exchange
Vascular intervention specialist OrbusNeich Medical Group Limited, a Wholly Owned Foreign Enterprise (WOFE) based in...
Immorna’s JCXH-221 mRNA Vaccine Cleared by FDA for Phase I/II Study
Immorna (Hangzhou) Biotechnology Co., Ltd has announced that the US FDA has cleared its investigational...
Henlius Biotech Partners with Shantou Central Hospital for Clinical Study Collaboration
China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with...
AnchorDx Initiates US Registrational Study for UriFind Urothelial Carcinoma Diagnostic
China-based AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has announced the initiation...
Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano
Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano...
Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...
Saint Medical Raises Pre-Series B Funding for Structural Heart Disease Solutions
Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly...
Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...
Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the...
Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug
China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...
Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...